# Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.

> **NCT04479553** · — · UNKNOWN · sponsor: **Zhong Wang** · enrollment: 30000 (estimated)

## Conditions studied

- Safety Surveillance
- Adverse Drug Events
- Adverse Drug Reactions
- Severe Adverse Events
- Severe Adverse Reactions

## Interventions

- **DRUG:** Qizhi Tongluo Capsules

## Key facts

- **NCT ID:** NCT04479553
- **Lead sponsor:** Zhong Wang
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-17
- **Primary completion:** 2023-09
- **Final completion:** 2023-12
- **Target enrollment:** 30000 (ESTIMATED)
- **Last updated:** 2022-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04479553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04479553, "Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04479553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*